Latest news with #EoE
Medscape
3 days ago
- Business
- Medscape
EoE Prevalence in US Reaches 1 in 700, Costs $1B Annually
The prevalence of eosinophilic esophagitis (EoE) has increased fivefold in the United States since 2009, now affecting about 1 in 700 people and totaling $1.32 billion in annual healthcare costs, according to recent research. Although EoE has been considered a rare disease, the chronic condition is becoming more common, and healthcare providers should expect to encounter EoE in clinical settings, the study authors wrote. 'Our last assessment of the prevalence and burden of EoE was more than 10 years ago, and we had a strong suspicion we would continue to see increased numbers of patients with EoE and an increasing cost burden related to the condition in the United States,' said senior author Evan S. Dellon, MD, MPH, professor of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine, Chapel Hill, North Carolina. 'EoE is becoming more common,' Dellon said. 'Healthcare providers should expect to see EoE in their practices, including in the primary care setting, emergency departments, allergy practices, GI [gastrointestinal] practices, ENT [ear, nose, and throat] clinics, and endoscopy suites.' The study was published in Clinical Gastroenterology and Hepatology . Estimating EoE Prevalence Dellon and colleagues analyzed the Merative MarketScan Commercial Claims and Encounters and Medicare Fee-for-Service databases to calculate the annual prevalence of EoE, as well as age- and sex-stratified estimates standardized to the US population. They also calculated healthcare utilization, including medications and endoscopic procedures, to estimate annual EoE-associated costs. Since the EoE billing code was introduced in 2008, the analysis included 2009-2022 MarketScan and 2009-2017 Medicare data. In the MarketScan database, the research team identified 20,435 EoE cases in 2022, with a mean age of 38 years, 16% younger than 18 years, 62% men, and 41% with a comorbid allergic disease code. The most common symptoms and diagnoses were dysphagia (39%), abdominal pain or dyspepsia (24%), and esophageal stricture (19%). Over time, patients also had previous codes for comorbid allergic diseases (64%), dysphagia (62%), or esophageal stricture (32%). In the Medicare database, the research team identified 1913 EoE cases in 2017, with a mean age of 73 years, 47% men, 90% non-Hispanic White, and 36% with a comorbid allergic disease. The most common symptoms and diagnoses were dysphagia (49%), abdominal pain or dyspepsia (35%), and esophageal stricture (30%). Over time, patients also had codes for comorbid allergic diseases (64%), dysphagia (65%), or esophageal stricture (42%). The database numbers translated to EoE prevalences of about 163 cases per 100,000 people in MarketScan in 2022 and 64 cases per 100,000 people in Medicare in 2017. Since 2009, there has been a fivefold increase in prevalence in both databases. In MarketScan, the prevalence was higher among men than among women, at 204 vs 122 cases per 100,000 people. For both sexes, peak prevalence occurred between ages 40 and 44. In Medicare, prevalence was also higher among men than among women, at 79 vs 55 cases per 100,000 people. Peak prevalence occurred between ages 65 and 69. Standardized to the US population, EoE prevalence was 142.5 cases per 100,000 people, extrapolating to 472,380 cases. The overall prevalence was approximately 1 in 700, with rates of 1 in 617 for those younger than 65 years and 1 in 1562 for those aged ≥ 65 years. 'The rapidly increasing prevalence year over year for the entire timeframe of the study was surprising, as were our estimates of the total number of EoE patients in the US, which suggests that EoE is no longer a rare disease and is now seen in about 1 in 700 people,' Dellon said. 'This almost triples our prior estimates of 1 in 2000 from 10 years ago, with all trends suggesting that the prevalence will continue to increase.' Calculating EoE Costs In terms of procedures, endoscopy with dilation or biopsy was used in about 60%-70% of patients with EoE in both MarketScan and Medicare during the years analyzed. In addition, upper endoscopy with biopsy was coded in 80%-90% of patients, guidewire-based dilation in 11%-17% of patients, and balloon-based dilation in 13%-20% of patients. In terms of prescription medications, proton pump inhibitors (41%) and topical steroids (26%) were the most common in MarketScan in 2022, as well as in Medicare in 2017, at 32% and 9%, respectively. When looking at costs by age and sex, the male cohort with the highest costs was aged 10-14 years, estimated at $106.7 million. Among the female cohort, the highest costs were associated with ages 15-19, estimated at $46.5 million. Overall, total EoE-associated healthcare costs were estimated to be $1.04 billion in 2017, and when adjusted for inflation, the costs were estimated at $1.32 billion in 2024. This is likely an underestimate, the authors wrote, given that EoE prevalence has likely increased for ages 65 or older since 2017 and for all ages since 2022. 'Researching the prevalence and costs is essential to improving patient care by highlighting the growing burden of this recently recognized and growing chronic disease, guiding policy and insurer decisions, and advocating for better access to effective treatments and support for patients,' said Joy Chang, MD, assistant professor of medicine in the Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan. Chang, who wasn't involved with this study, specializes in eosinophilic GI diseases and researches patient-physician preferences and decision-making in EoE care. 'Clinicians should remain vigilant for symptoms, utilize guideline-based diagnostic approaches, and consider both medical and dietary treatment strategies to optimize patient outcomes and reduce long-term costs,' she said. 'Increased awareness and timely intervention can help mitigate the growing impact of this chronic condition.' The study was supported by a National Institutes of Health grant and used resources from the University of North Carolina Center for Gastrointestinal Biology and Disease. Dellon reported receiving research funding from and having consultant roles with numerous pharmaceutical companies and organizations. Chang reported having no relevant disclosures.
Medscape
27-05-2025
- Business
- Medscape
Etrasimod Shows Promise in Eosinophilic Esophagitis
Etrasimod, a once-daily oral selective sphingosine-1-phosphate receptor modulator, is well tolerated and effective in treating eosinophilic esophagitis (EoE), demonstrating sustained histologic and endoscopic improvements over 52 weeks. METHODOLOGY: Etrasimod, currently approved in adults with moderate to severe ulcerative colitis, blocks lymphocyte trafficking to inflamed mucosal tissues and may offer a promising option for treating EoE. Researchers conducted an international phase 2 multicenter trial to assess the efficacy and safety of etrasimod vs placebo in patients (age, 18-65 years) with previously diagnosed and histologically active EoE. Patients were randomized to receive oral 1 mg etrasimod, 2 mg etrasimod, or placebo once daily for 24 weeks, with stratification according by history of dilation and concurrent proton pump inhibitor therapy. Patients who completed the initial treatment phase entered a 28-week extension period, during which they either continued their etrasimod dose or were randomly switched from placebo to 1 or 2 mg etrasimod. The primary endpoint was a percentage change in the esophageal peak eosinophil count from baseline to week 16; safety was assessed through week 52. TAKEAWAY: Researchers randomized 108 patients: 41 to receive 2 mg etrasimod, 39 to receive 1 mg etrasimod, and 28 to receive placebo; 85 patients completed the double-blind period and entered the extension period. At week 16, only etrasimod 2 mg significantly reduced peak eosinophil count from baseline vs placebo ( P = .010); however, at week 24, both 1 and 2 mg doses showed significant reductions ( P = .0022 and P < .0001, respectively). = .010); however, at week 24, both 1 and 2 mg doses showed significant reductions ( = .0022 and < .0001, respectively). Endoscopic and histologic severity scores improved with 2 mg etrasimod and both doses, respectively, at week 24, with benefits sustained through week 52. Significant improvements in Dysphagia Symptom Questionnaire scores were noted at week 24 in patients without prior endoscopic dilation compared with patients receiving placebo. Gastrointestinal disorders were the most common treatment-emergent adverse events, occurring in 27% (2 mg), 33% (1 mg), and 50% (placebo). Three cases of mild or moderate bradycardia were reported. IN PRACTICE: 'Etrasimod offers a promising new therapeutic approach for eosinophilic oesophagitis, addressing the complexities of [type 2 helper T cells]–driven inflammation and the challenges posed by preexisting fibrotic changes,' an expert wrote in an accompanying editorial. 'Etrasimod's simple administration, independent of meals, could potentially increase patient compliance.' SOURCE: The study was led by Evan S. Dellon, MD, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine in Chapel Hill. It was published online in The Lancet Gastroenterology & Hepatology . LIMITATIONS: This study was not powered to assess dysphagia symptoms. It included a high proportion of patients with stenosis and prior dilation and few with atopic conditions, relative to other reported EoE studies. The extension phase involved a limited number of patients. DISCLOSURES: This study was funded by Pfizer. Nine authors declared being current or former employees of Pfizer and holding stock or stock options. Several others reported receiving grants, honoraria, fees, or travel support from, holding stocks of, or having other ties with Pfizer and other pharmaceutical companies.
Yahoo
15-05-2025
- Health
- Yahoo
Eosinophilic Esophagitis Market Set to Surge as New Research Unveils Breakthrough Treatments
The dynamics of the eosinophilic esophagitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as APT-1011 (Ellodi Pharmaceuticals), tezepelumab (AstraZeneca,) and ESO-101 (EsoCap) during the forecast period (2024–2034). LAS VEGAS, May 15, 2025 /PRNewswire/ -- Eosinophilic esophagitis (EoE) is a multifaceted disease marked by diverse clinical features, including variations in age of onset, symptoms, disease progression, comorbid conditions, and treatment responses. Although diagnosing and managing EoE remains challenging, both clinical and experimental studies consistently support that the disease is primarily driven by a CD4+ T helper type 2 (Th2) allergic inflammatory reaction to food allergens in the esophageal lining. In 2023, around 800,000 prevalent cases of EoE were diagnosed across the 7MM, with this number projected to grow at a moderate CAGR through 2034. Current eosinophilic esophagitis treatment guidelines include dietary modifications, medications, and endoscopic procedures. Among pharmacological options, proton pump inhibitors (PPIs) and corticosteroids are commonly used, though they are frequently associated with high relapse rates. The market holds limited approved eosinophilic esophagitis medications such as DUPIXENT (dupilumab) and JORVEZA (budesonide). Learn more about the treatment options for eosinophilic esophagitis @ Medications for Eosinophilic Esophagitis Treatment DUPIXENT (dupilumab) is a human IgG4 monoclonal antibody that blocks IL-4 and IL-13 signaling by targeting the IL-4Rα subunit, which is common to both IL-4 and IL-13 receptor complexes. In May 2022, the U.S. FDA approved DUPIXENT for the treatment of eosinophilic esophagitis in adults and adolescents aged 12 and older who weigh at least 40 kilograms (88 pounds). More recently, in January 2024, the FDA expanded its indication to include children as young as 1 year old with EoE. DUPIXENT eosinophilic esophagitis received Breakthrough Therapy Designation (BTD) from the FDA in September 2020 for treating EoE in patients aged 12 and older. DUPIXENT eosinophilic esophagitis was developed using Regeneron's VelocImmune technology and has been co-developed with Sanofi since 2007. JORVEZA (budesonide), developed by Dr. Falk Pharma GmbH, is a non-halogenated glucocorticoid that exerts its primary anti-inflammatory effect through activation of the glucocorticoid receptor. In January 2018, JORVEZA received marketing authorization for treating EoE in adults over 18 years old. It also holds orphan drug designation. For acute treatment, the recommended dosage is two 1 mg tablets taken twice daily. To know more about the eosinophilic esophagitis treatment, visit @ Eosinophilic Esophagitis Drug Information Despite the recent FDA and EMA approvals of two eosinophilic esophagitis medications, effective curative options remain limited. Concerns around the safety and efficacy profiles of these newly approved drugs, along with the lack of standardized dosing guidelines, often deter gastroenterologists from incorporating them into routine clinical practice. The emerging eosinophilic esophagitis treatment landscape consists of tezepelumab (AstraZeneca), APT-1011 (Ellodi Pharmaceutical), ESO-101 (EsoCap), and others. The eosinophilic esophagitis market presents a wide opportunity for these players to capitalize on the untapped eosinophilic esophagitis drugs market. Discover which therapies are expected to grab major eosinophilic esophagitis drug market share @ Eosinophilic Esophagitis Mechanism of Action APT-1011 is an innovative oral formulation of fluticasone that utilizes Adare's proprietary AdvaTab technology, enabling targeted topical delivery to the esophagus. It has been granted Orphan Drug Designation (ODD) by both the FDA and EMA, along with Fast Track Designation (FTD) from the FDA. These regulatory designations were based on clinical data demonstrating histological remission and symptom improvement following a 12-week induction phase, as well as the sustained maintenance of these benefits. Following the successful completion of the FLUTE 1 (Phase IIb) and FLUTE 2 (Phase III) studies, the company has initiated FLUTE 3, a second ongoing Phase III trial. TEZSPIRE (tezepelumab) is a potentially first-in-class human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a key cytokine that initiates multiple inflammatory pathways. It has also received ODD from the FDA for the treatment of eosinophilic esophagitis. The drug is currently being evaluated in a Phase III clinical trial (CROSSING) to assess its efficacy and safety in EoE patients. ESO-101 is a novel, esophagus-targeted formulation of mometasone furoate, designed to enhance mucosal contact and maximize drug deposition in the esophagus. It holds promise for delivering meaningful clinical improvements in EoE patients. ESO-101 has received ODD from the FDA and has successfully completed a Phase II trial in EoE, with results already published. Discover more about eosinophilic esophagitis drugs in development @ Eosinophilic Esophagitis Clinical Trials The anticipated launch of these emerging eosinophilic esophagitis treatments are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the eosinophilic esophagitis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for eosinophilic esophagitis in the 7MM is expected to grow from USD 1.8 billion in 2023 at a significant CAGR by 2034. This expansion across the 7MM will be due to the rising awareness of the disease and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. DelveInsight's latest published market report titled Eosinophilic Esophagitis Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the eosinophilic esophagitis country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The eosinophilic esophagitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Prevalence of EoE Age-specific Cases of EoE Gender-specific Cases of EoE The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM eosinophilic esophagitis market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this eosinophilic esophagitis market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the eosinophilic esophagitis market. Also, stay abreast of the mitigating factors to improve your market position in the eosinophilic esophagitis therapeutic space. Related Reports Eosinophilic Esophagitis Epidemiology Forecast Eosinophilic Esophagitis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted eosinophilic esophagitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Eosinophilic Esophagitis Pipeline Eosinophilic Esophagitis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key eosinophilic esophagitis companies, including Sanofi, Regeneron, AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, DBV Technologies, Celldex Therapeutics, NexEos Bio, Aqilion, Quorum Innovations, Serpin Pharma, RAPT Therapeutics, among others. Eosinophilic Disorder Market Eosinophilic Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic disorder companies including Children's Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, among others. Eosinophilic Disorder Pipeline Eosinophilic Disorder Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key eosinophilic disorder companies, including Children's Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
14-05-2025
- Health
- Medscape
Train Advanced Practice Providers in Transnasal Endoscopy?
Advanced practice providers (APPs) can be trained to perform transnasal endoscopy (TNE) with a single-use ultra-slim gastroscope with only topical anesthesia, a pilot study showed. 'Our study showed that TNE can be performed safely by APPs, is well tolerated by patients, and significantly impacted patient management,' Whitney Kucher, PA-C, with Northwestern Medicine, Chicago, told Medscape Medical News . 'The chief benefit of having APPs perform TNEs is increasing patient access and expediting management of upper GI [gastrointestinal] symptoms in patients,' said Kucher who presented the study at Digestive Disease Week (DDW) 2025. The EvoEndo single-use endoscopy system received 510(k) clearance from the US Food and Drug Administration in early 2022. The system includes a sterile, single-use, flexible gastroscope designed for unsedated transnasal upper endoscopy and a small portable video controller. Unsedated TNE can be used to evaluate and diagnose a wide range of upper GI conditions that may require frequent monitoring, including eosinophilic esophagitis (EoE), dysphagia, celiac disease, gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), malabsorption, and abdominal pain. Kucher and colleagues assessed the ability for APPs to use the EvoEndo system to perform safe and accurate esophageal assessment using in-office TNE, following training. TNE training lasted about 4 weeks and consisted of a stepwise approach involving lectures, simulation-based training, and hands-on supervised TNEs (10 per APP). Once training was completed, and after providing consent, 25 patients were enrolled to undergo supervised TNE by an APP. Their mean age was 55 years, and 58% were women. Indications for TNE were uncontrolled GERD symptoms in 12 patients, history of EoE in six patients, high-risk screening for BE in five patients, and dysphagia in two patients. Technical success was achieved in all but one patient (96%), and there were no adverse events. All 25 patients completed the procedure, with 17 (72%) giving it a TNEase score of 1 (with ease/no discomfort) or 2 (mild/occasional discomfort). Only two patients reported a score of 4 (very uncomfortable) but still completed the exam. The average TNE procedure time was 7.3 minutes. TNE findings changed management in 23 of 25 (92%) patients. The test led to a change in proton pump inhibitor dosing or interval in 14 patients (56%). Esophagogastroduodenoscopy (EGD) interval was extended in five patients (20%) and scheduled sooner in three patients (12%). Two patients (8%) had no change in management. The study team said more data are needed in terms of learning curves, competency metrics, and health economics before widespread adoption can be supported. 'We are working on developing a standardized training plan so we can train more GI APPs in our department. We have plans to start an APP-driven TNE program in the coming months,' Kucher told Medscape Medical News . Caveats and Cautionary Notes Commenting on this study for Medscape Medical News , Amitabh Chak, MD, president of the American Society for Gastrointestinal Endoscopy, noted that the results are 'similar to older studies where TNE appeared quite promising and APPs could be trained. There have been previous studies that APPs can perform colonoscopies and EGDs.' Chak cautioned that previous studies showed that it took at least 50 supervised examinations for APPs to achieve the needed skills. 'Intubation transnasally can be painful for patients if not done with skill. Cognitive skills take longer. The gastroesophageal junction is dynamic, and recognition of subtle pathology takes training,' Chak noted. 'TNE has been around at least two decades. The challenge with uptake of TNE for Barrett's screening has been acceptance by primary care physicians, patients and payers,' Chak told Medscape Medical News .
Business Insider
07-05-2025
- Business
- Business Insider
Eupraxia Pharmaceuticals reports Q1 net loss $6.8M vs. $6.2M last year
The Company had cash of $27.5M as of March 31, down from $33.1M at the end of the Q4.'We recently achieved a significant clinical milestone with the release of positive nine-month data from our ongoing open-label, dose-escalation Phase 1b/2a RESOLVE trial, which continue to support EP-104GI as a potentially transformative therapy for eosinophilic esophagitis,' said James Helliwell, CEO of Eupraxia. 'The sustained or improved treatment outcomes observed over a nine-month period after a single treatment with 48mg dose of EP-104GI is a promising finding in the treatment of EoE with an injectable delivery system. We believe these results provide further evidence of the precision and durability of our DiffuSphere technology and provide a strong foundation as we advance into higher-dose cohorts in the coming quarters.' Protect Your Portfolio Against Market Uncertainty
